VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Donato on Advances in the Prevention of GVHD

Michele L. Donato, MD
Published: Wednesday, Apr 09, 2014

Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theurer Cancer Center, discusses advances in the prevention of graft-versus-host disease (GVHD).

It is clear now that younger donors perform better: They experience less GVHD, better disease control, and fewer treatment-related complications. Donor selection is crucial in the prevention of GVHD, Donato says, and physicians now have the capacity to select donors where the indigence of GVHD will be less.

GVHD is of particular concern in haploidentical and half-match transplants, but the process of giving post-transplant, high-dose cyclophosphamide to kill activated T cells has been effective in this space. This process has made it possible to do haploidentical and half-match transplants with no more ​GVHD than in a fully-matched sibling and has also been looked at in unrelated donors.

Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theurer Cancer Center, discusses advances in the prevention of graft-versus-host disease (GVHD).

It is clear now that younger donors perform better: They experience less GVHD, better disease control, and fewer treatment-related complications. Donor selection is crucial in the prevention of GVHD, Donato says, and physicians now have the capacity to select donors where the indigence of GVHD will be less.

GVHD is of particular concern in haploidentical and half-match transplants, but the process of giving post-transplant, high-dose cyclophosphamide to kill activated T cells has been effective in this space. This process has made it possible to do haploidentical and half-match transplants with no more ​GVHD than in a fully-matched sibling and has also been looked at in unrelated donors.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Publication Bottom Border
Border Publication
x